Novartis Reaffirms 2026 Sales Outlook, Raises Core Operating Income Guidance
Novartis reaffirmed 2026 sales growth guidance in the low single digits and revised its core operating income outlook to low single-digit growth, from a prior expectation of a low single-digit decline. The company reported a $1.9 billion impairment charge tied to Avidity Biosciences.